Using Big Data for Bioengineering Antibodies and Drug Discovery
Continue to learn about the cutting edge of computational immuno-oncology through a partnership between NCI and the Society for Immunotherapy of Cancer (SITC)!
In this webinar, Drs. Liz Wood, founder and CEO of JURA Bio, Inc., and Sandhya Prabhakaran, of the Moffitt Cancer Center, will discuss how to use big data for bioengineering antibodies and drug discovery in cancer research.
The SITC-NCI Computational Immuno-Oncology Webinar Series features eight, one-hour-long webinars designed to educate early-career scientists on computational immuno-oncology, increase participants’ awareness of and engagement in NCI-supported Cancer MoonshotSM Immunotherapy Networks, and fulfill the Blue Ribbon Panel’s goal of accelerating progress in cancer research.
Dr. Wood is the co-founder and CEO of JURA Bio, Inc., an early-stage therapeutics company focused on developing and delivering cell-based therapies for treating autoimmune and immune-related neurodegenerative diseases.
Dr. Prabhakaran is an applied research scientist at the Integrated Mathematical Oncology Department of the Moffitt Cancer Centre.